Prednisone and Your Bones: A Patient's Guide to Preventing Silent Skeletal Damage

Diane, a 54-year-old retired schoolteacher from Ohio, had been taking prednisone for her rheumatoid arthritis for nearly four years when she fractured her wrist reaching for a casserole dish. The fall that caused the break was minor — the kind of stumble most people walk away from. Her orthopedic surgeon ordered a bone density scan. The results showed she had osteoporosis. "Nobody ever mentioned my bones," she said. "We talked about my joints, my immune system, my blood sugar. But my bones? Never once."

Diane's experience is not unusual. Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis in the United States, and it remains one of the most underrecognized complications of long-term corticosteroid therapy. Patients receiving prednisone for conditions ranging from lupus to asthma to inflammatory bowel disease are losing bone density at measurable rates — often without any symptoms until a fracture occurs.

At PrednisoneMD, we are committed to giving patients the complete picture of what corticosteroid therapy involves, including the side effects that don't always make it onto the discharge paperwork. Bone health is not a footnote. For patients on extended prednisone therapy, it is a clinical priority that demands proactive attention.

How Prednisone Damages Bone: The Mechanism Explained

Healthy bone is not static. It is living tissue in a constant state of remodeling — old bone cells are broken down by cells called osteoclasts, and new bone is built by cells called osteoblasts. This cycle, when balanced, maintains skeletal strength and density throughout life.

Glucocorticoids like prednisone disrupt this balance in multiple ways simultaneously. They suppress osteoblast activity, meaning new bone formation slows significantly. At the same time, they increase osteoclast lifespan, accelerating bone breakdown. The net result is a measurable loss of bone mineral density that begins within the first three to six months of therapy — often before patients or their physicians have thought to evaluate it.

Prednisone also interferes with calcium absorption in the intestines and increases calcium excretion through the kidneys, creating a net calcium deficit that the body compensates for by drawing calcium from bone. Additionally, corticosteroids suppress sex hormone production — both estrogen and testosterone — which are critical regulators of bone density in adults of all genders.

The skeletal sites most vulnerable to glucocorticoid-induced bone loss are the trabecular-rich areas: the spine and the hip. These are also the fracture sites associated with the most serious consequences, including vertebral compression fractures and hip fractures that can result in lasting disability.

"I Didn't Know I Was at Risk": The Screening Gap

Marco, a 61-year-old from suburban Chicago, had been managing chronic obstructive pulmonary disease (COPD) with periodic prednisone courses for over a decade. He considered his use "intermittent" and assumed the risks associated with long-term use did not apply to him. His pulmonologist eventually ordered a DEXA scan — a dual-energy X-ray absorptiometry test that measures bone mineral density — after Marco mentioned back pain during a routine visit. The scan revealed osteopenia, a precursor to osteoporosis.

"I thought because I wasn't on it every single day, I was fine," Marco recalled. "But apparently all those courses add up."

The American College of Rheumatology (ACR) has published specific guidelines for the prevention and treatment of GIOP. These guidelines recommend that any patient expected to take prednisone at a dose of 2.5 mg or more per day for three or more months should be evaluated for fracture risk. This includes obtaining a baseline DEXA scan and calculating a FRAX score — a validated fracture risk assessment tool developed by the World Health Organization that estimates a patient's 10-year probability of major osteoporotic fracture.

Despite these guidelines, studies consistently show that a significant proportion of eligible patients never receive a baseline bone density evaluation. If you have been on prednisone for an extended period and have never had a DEXA scan, asking your physician about one is a medically justified and appropriate request.

Calcium and Vitamin D: The Non-Negotiable Foundation

For patients on long-term corticosteroids, the ACR guidelines are explicit: calcium and vitamin D supplementation are considered standard of care, not optional. The recommended daily calcium intake for adults on glucocorticoids is 1,000 to 1,200 mg per day, obtained through a combination of dietary sources and supplementation as needed. Vitamin D intake of 600 to 800 IU daily is the general population recommendation, but many specialists recommend higher amounts — up to 1,500 to 2,000 IU — for patients on corticosteroids, with dosing guided by serum 25-hydroxyvitamin D levels.

Calcium-rich foods — dairy products, fortified plant-based milks, leafy greens, and canned fish with bones — should form the dietary foundation, with supplements used to close the gap. Calcium carbonate is best absorbed with food, while calcium citrate can be taken with or without meals and may be preferable for patients with acid reflux or those on proton pump inhibitors.

Vitamin D levels are straightforward to measure with a standard blood test. If your physician has not checked your vitamin D status, this is worth raising, particularly given that vitamin D insufficiency is common across the United States, especially in northern states during winter months.

Beyond Supplements: Pharmacological Bone Protection

For patients at moderate or high fracture risk — as determined by FRAX scores and clinical factors — calcium and vitamin D alone are insufficient. The ACR guidelines recommend initiating prescription bone-protective therapy in these patients, and the most commonly prescribed agents are bisphosphonates.

Oral bisphosphonates such as alendronate (Fosamax) and risedronate (Actonel) are typically first-line options. They work by inhibiting osteoclast activity, slowing the rate of bone breakdown. For patients who cannot tolerate oral bisphosphonates, intravenous zoledronic acid (Reclast) offers an annual infusion alternative.

For postmenopausal women and older men at high fracture risk, newer agents such as denosumab (Prolia) — a biologic that targets a key driver of osteoclast activity — and teriparatide (Forteo), an anabolic agent that actively stimulates bone formation, may be considered. These are typically specialist-initiated therapies, and decisions about their use should involve a rheumatologist or endocrinologist familiar with GIOP management.

Lifestyle Factors That Support Bone Health

Medication and supplementation are the clinical backbone of GIOP prevention, but lifestyle factors contribute meaningfully to outcomes. Weight-bearing exercise — walking, low-impact aerobics, resistance training — stimulates bone formation and should be incorporated into the routine of any patient medically able to do so. Smoking cessation is particularly important, as tobacco use independently accelerates bone loss. Alcohol consumption should be moderated, as heavy intake impairs calcium absorption and is associated with increased fracture risk.

Fall prevention also deserves attention, especially for older patients or those experiencing prednisone-related side effects such as muscle weakness. Home safety assessments, balance training, and appropriate footwear can reduce the risk of the falls that most commonly lead to fractures in people with reduced bone density.

Advocating for Your Skeletal Health

Diane now sees a rheumatologist who monitors her bone density annually and has her on a bisphosphonate regimen. Her most recent scan showed stabilization. "I wish someone had told me earlier," she said. "Four years is a long time to be losing bone without anyone looking."

If you are taking prednisone — whether for months or years — your bones deserve to be part of the conversation. Ask your physician about your fracture risk. Request a DEXA scan if you have not had one. Confirm that your calcium and vitamin D intake meets the recommendations for patients on corticosteroids. And if your risk warrants it, discuss whether prescription bone-protective therapy is appropriate for you.

The skeletal consequences of long-term prednisone use are serious, but they are not inevitable. With the right monitoring and the right interventions, patients can protect their bones while continuing the therapy their underlying condition requires. That is what informed, proactive care looks like — and it begins with knowing what questions to ask.